Preview

Артериальная гипертензия

Расширенный поиск

НОВЫЕ ЕВРОПЕЙСКИЕ РЕКОМЕНДАЦИИ ПО АРТЕРИАЛЬНОЙ ГИПЕРТОНИИ: ДОЛГОЖДАННЫЕ ОТВЕТЫ И НОВЫЕ ВОПРОСЫ

https://doi.org/10.18705/1607-419X-2014-20-1-19-26

Полный текст:

Аннотация

В статье рассмотрены основные отличия рекомендаций 2013 года Европейского общества по артериальной гипертензии и Европейского общества кардиологов от предыдущей версии. Особое внимание уделено разделу, касающемуся выбору антигипертензивной терапии, также рассматриваются вопросы,  ответы на которые еще предстоит найти.

Об авторе

Ж. Д. Кобалава
Российский университет дружбы народов, Москва
Россия

Доктор медицинских наук, профессор, заведующая кафедрой пропедевтики внутренних болезней, заведующая кафедрой кардиологии и клинической фармакологии факультета повышения квалификации медицинских работников ФГБОУ ВПО «Российский университет дружбы народов» Минобрнауки России.

Контактная информация: Городская клиническая больница № 64, кафедра пропедевтики внутренних болезнейФГБОУ ВПО «Российский университет дружбы народов» Минобрнауки России, ул. Вавилова, д. 61, Москва, Россия, 117292.  E-mail: zkobalava@mail.ru (Кобалава Жанна Давидовна).



Список литературы

1. Guidelines Sub-Committee. 2003 European Society of Hypertension — European Society of Cardiology guidelines for the management of arterial hypertension // J. Hypertens. — 2003. — Vol. 21, № 6. — P. 1011–1053.

2. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G. et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension // J. Hypertens. — 2007. — Vol. 25, № 9. — P. 1105–1187.

3. Mancia G., Fagard R., Narkiewicz R., Redon J., Zanchetti A., Bohm M. et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension // J. Hypertens. — 2013. — Vol. 31, № 7. — P. 1281–1357.

4. ESH/ESC Task Force for the management of arterial hypertension. 2013 Practice Guidelines for the management of (ESH) and the European Society of Cardiology (ESC) // J. Hyper- inhibitor or calcium channel blocker vs diuretic: The Antihypertens. — 2013. — Vol. 31, № 10. — P. 1925–1938.

5. Mancia G., Laurent S., Agabiti-Rosei E., Ambrosioni E., Burnier M., Caulield M.J. et al. Reappraisal of the European guidelines on hypertension management: a European Society of Hypertension Task Force document // J. Hypertens. — 2009. — Vol. 27, № 11. — P. 2121–2158.

6. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. — 2008. — Vol. 358, № 24. — P. 2560–2572.

7. Beckett N.S., Peters R., Fletcher A.E., Staessen J.A., Liu L., Dumitrascu D. et al. Treatment of hypertension in patients 80 years of age or older // N. Engl. J. Med. — 2008. — Vol. 358, № 18. — P. 1887–1898.

8. Yusuf S., Diener H.C., Sacco R.L., Cotton D., Ounpuu S., Lawton W.A. et al. Telmisartan to prevent recurrent stroke and cardiovascular events // N. Engl. J. Med. — 2008. — Vol. 359, № 12. — Р. 1225–1237.

9. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events // N. Engl. J. Med. —2008. — Vol. 358, № 15. — P. 1547–1559.

10. Telmisartan Randomized Assessment Study in ACE intolerant subjects with cardiovascular disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial // Lancet. — 2008. — Vol. 372, № 9644. — P. 1174–1183.

11. Jamerson K., Weber M.A., Bakris G.L., Dahlof B., Pitt B., Shi V. et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients // N. Engl. J. Med. — 2008. — Vol. 359, № 23. — P. 2417–2428.

12. The ACCORD Study Group. Effects of intensive blood pressure control in type 2 diabetes mellitus // N. Engl. J. Med. — 2010. — Vol. 362, № 17. — P. 1575–1585.

13. Sandset E.C., Bath P.M., Boysen G., Jatuzis D., Korv J., Luders S. et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial // Lancet. — 2011. — Vol. 377, № 9767. — P. 741–750

14. Haller H., Ito S., Izzo J.L., Januszewicz A., Katayama S., Menne J. et al. ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes // N. Engl. J. Med. — 2011. — Vol. 364, № 10. — P. 907–917.

15. Parving H.H., Brenner B.M., McMurray J.V., de Zeeuw D., Haffer S.M., Solomon S.D. Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes // N. Engl. J. Med. — 2012. — Vol. 367, № 23. — P. 2204–2213.

16. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations

17. from prospective epidemiological studies // Br. Med. J. — 2009. —Vol. 338. — 1665 p.

18. Williams B., Lacy P.S., Thom S.M., Cruickshank K., Stanton A., Collier D. et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study // Circulation. — 2006. — Vol. 113, № 9. — P. 1213–1225.

19. Boutouyrie P., Achouba A., Trunet P., Laurent S. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study // Hypertension. — 2010. — Vol. 55, № 6. — P. 1314–1322.

20. ALLHAT oficers and co-ordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // J. Am. Med. Assoc. — 2002. — Vol. 288, № 23. — P. 2981–2997.

21. Silvestri A., Galetta P., Cerquetani E., Marazzi G., Patrizi R., Fini M., Rosano G.M. Report of erectile dysfunction after therapy with beta blockers is related to patient knowledge of side- efects and is reversed by placebo // Eur. Heart. J. — 2003. — Vol. 24, № 21. — P. 1928–1932.

22. Hansson L., Lindholm L.H., Ekbom T., Dahlof B., Lanke J., Schersten B. et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study // Lancet. — 1999. — Vol. 354, № 9192. — P. 1751–1756.

23. Rutten F.H., Zuithoff N.P., Halk F., Grobbee D.E., Hoes A.W. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease // Arch. Intern. Med. — 2010. — Vol. 170, № 10. — P. 880–887.

24. National Institute for Health and Clinical Excellence. Hypertension (CG127): clinical management of primary hypertension in adults. http://www.nice.org.uk/guidance/CG127.

25. Zanchetti A., Mancia G. Longing for clinical excellence: a critical outlook into the NICE recommendations on hypertension managemen this nice always good? // J. Hypertens. — 2012. — Vol. 30, № 4. — P. 660–668.

26. Zanchetti A. Hypertension meta-analyses: irst rank evidence or second hand information? // Nat. Rev. Cardiol. — 2011. — Vol. 8, № 5. — P. 249–251.

27. Messerli F.H., Makani H., Benjo A., Romero J., Alviar C., Bangalore S. Antihypertensive eficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring. A meta-analyses of randomized trials // J. Am. Coll. Cardiol. — 2011. — Vol. 57, № 5. — P. 590–600.

28. Roush G.C., Holford T.R., Guddati A.K. Chlortalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses // Hyperten-sion. — 2012 — Vol. 59, № 6. — P. 1110–1117.

29. Dorsch M.P., Gillespie B.W., Erickson S.R., Bleske B.E., Weder A.B. Chlortalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis // Hypertension. — 2011. — Vol. 57, № 4. — P. 689–694.

30. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials // Arch. Intern. Med. — 2005. — Vol. 165, № 12. — P. 1410–1419.

31. Verdecchia P., Reboldi G., Angeli F., Gattobigio R., Bentivoglio M., Thijs L. et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention // Hypertension. — 2005. — Vol. 46, № 2. — P. 386–392.

32. Strauss M.H., Hall A.S. Do angiotensin receptor blockers increase the risk of myocardial infarction? Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox // Circulation. — 2006. — Vol. 114, № 8. —P. 838–854.

33. van Vark L.C., Bertrand M., Akkerhuis K.M., Brugts J.J., Fox K., Mourad J.J., Boersma E. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients // Eur. Heart. J. — 2012. — Vol. 33, № 16. — P. 2088–2097.

34. Liu L., Zhang Y., Liu G., Li W., Zhang X., Zanchetti A. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo controlled trial in Chinese hypertensive patients // J. Hypertens. — 2005. — Vol. 23, № 12. — P. 2157–2172.

35. Dalhof B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., aulield M. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required vs. atenolol adding bendrolumethiazide as required in the Anglo-Scandinavian. Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA) a multicentre randomised controlled trial // Lancet. — 2005. — Vol. 366, № 9489. — P. 895–906.

36. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U. et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol // Lancet. — 2002. — Vol. 359, № 9311. — P. 995–1003.

37. Hansson L., Lindholm L.H., Niskanen L., Lanke J., Hedner T., Niklason A. et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial // Lancet. — 1999. — Vol. 353, № 9153. — P. 611–616.

38. Hansson L., Hedner T., Lund-Johansen P., Kjeldsen S.E., Lindholm L.H., Sylversten J.O. et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study // Lancet. — 2000. — Vol. 356, № 9227. — P. 359–365.


Для цитирования:


Кобалава Ж.Д. НОВЫЕ ЕВРОПЕЙСКИЕ РЕКОМЕНДАЦИИ ПО АРТЕРИАЛЬНОЙ ГИПЕРТОНИИ: ДОЛГОЖДАННЫЕ ОТВЕТЫ И НОВЫЕ ВОПРОСЫ. Артериальная гипертензия. 2014;20(1):19-26. https://doi.org/10.18705/1607-419X-2014-20-1-19-26

For citation:


Kobalava Z.D. NOVEL 2013 EUROPEAN SOCIETY OF HYPERTENSION AND EUROPEAN SOCIETY OF CARDIOLOGY GUIDELINES FOR THE MANAGEMENT OF ARTERIAL HYPERTENSION: LONG-EXPECTED ANSWERS AND NEW QUESTIONS. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2014;20(1):19-26. (In Russ.) https://doi.org/10.18705/1607-419X-2014-20-1-19-26

Просмотров: 660


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)